Mitoxantrone as single agent in the treatment of advanced breast cancer: clinical experience at Siriraj Hospital.
Article
in English
| IMSEAR
| ID: sea-43216
ABSTRACT
A total of 35 patients with advanced breast cancer were treated with mitoxantrone, 14 mg/m2 I.V. every 3 weeks. Of these, 27 patients or 78 lesions could be evaluated for response and all 35 patients for toxicity. The overall response rate (CR + PR) was 35 per cent (or CR + PR + SD = 82%), ten lesions achieved a complete response and 17 lesions a partial response. The duration of response varied from a minimum of 2 months to more than 11 months (median = 4 months). Myelosuppression was the dose-limiting toxicity with moderate to severe degree in 19 patients. The most frequent severe degree in 19 patients. The most frequent non-hematologic toxicity was mild grade of nausea and vomiting (67%). No cardiotoxicity was noted in this study after the maximum cumulative dose of mitoxantrone 157.5 mg.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Breast Neoplasms
/
Aged
/
Female
/
Humans
/
Mitoxantrone
/
Adult
/
Middle Aged
Language:
English
Year:
1989
Type:
Article
Similar
MEDLINE
...
LILACS
LIS